Top

Published in:

Open Access 01-12-2021 | Pleural Mesothelioma | Research article

Integrating data from multidisciplinary Management of Malignant Pleural Mesothelioma: a cohort study

Authors: Laura Saracino, Chandra Bortolotto, Stefano Tomaselli, Elia Fraolini, Matteo Bosio, Giulia Accordino, Francesco Agustoni, David M. Abbott, Emma Pozzi, Dimitrios Eleftheriou, Patrizia Morbini, Pietro Rinaldi, Cristiano Primiceri, Andrea Lancia, Patrizia Comoli, Andrea R. Filippi, Giulia M. Stella

Published in: BMC Cancer | Issue 1/2021

Abstract

Background

Malignant pleural mesothelioma (MPM) is a rare and aggressive malignancy that most commonly affects the pleural layers. MPM has a strong association with asbestos, mainly caused by exposure to its biopersistent fibers in at least 80% of cases. Individuals with a chronic exposure to asbestos might develop disease with a 20–40-year latency with few or no symptoms. Such has been the case in the Italian regions of Piedmont and Lombardy, where industrial production of materials laden with asbestos, mainly cements, has been responsible for the onset of a large epidemic. Since 2018, a multidisciplinary team at San Matteo hospital in Pavia has been collecting data on over 100 patients with MPM. The main goal of this project is to define and describe an integrated profile for each MPM case at diagnosis by using data mining and partition analysis.

Methods

Here we bring together exhaustive epidemiologic, histologic and radiologic data of 88 MPM patients that came to our observation and draw correlations with predictive and prognostic significance.

Results

The median overall survival (OS) was 15.6 months. Most patients presented with pleural effusion, irrespective of disease stage. Quite unexpectedly, no statistically significant association was demonstrated between OS and TNM disease stage at diagnosis. Although average OS is similar in male and female patients, partition analysis of data underlined a significant differential hierarchy of predictor categories based on patient gender. In females with no smoking history, full chemotherapeutic regimens are associated with better outcomes. Moreover, concerning second line treatments, vinorelbine emerged as the most advantageous choice for female patients, whereas in the male subgroup no statistically significant difference resulted between gemcitabine and vinorelbine.

Conclusion

A multidisciplinary approach to MPM is mandatory to define better therapeutic approaches, personalize the management and improve patient outcomes.

Available only for authorised users

Pignochino Y, Dell'Aglio C, Inghilleri S, Zorzetto M, Basiricò M, Capozzi F, et al. The combination of sorafenib and everolimus shows antitumor activity in preclinical models of malignant pleural mesothelioma. BMC Cancer. 2015;15(1):374. https://doi.org/10.1186/s12885-015-1363-1.CrossRefPubMedPubMedCentral

Røe OD, Stella GM. Malignant pleural mesothelioma: history, controversy and future of a manmade epidemic. Eur Respir Rev. 2015;24(135):115–31. https://doi.org/10.1183/09059180.00007014.CrossRefPubMed

Berzenji L, Van Schil P. Multimodality treatment of malignant pleural mesothelioma. F1000Res. 2018 ;7: F1000 Faculty Rev-1681. doi: https://doi.org/10.12688/f1000research.15796.1.

Remon J, Passiglia F, Ahn MJ, Barlesi F, Forde PM, Garon EB, et al. Immune checkpoint inhibitors in thoracic malignancies: review of the existing evidence by an IASLC expert panel and recommendations. J Thorac Oncol. 2020;15(6):914–47. https://doi.org/10.1016/j.jtho.2020.03.006.CrossRefPubMed

Nicolini F, Bocchini M, Bronte G, Delmonte A, Guidoboni M, Crinò L, et al. Malignant pleural mesothelioma: state-of-the-art on current therapies and promises for the future. Front Oncol. 2020;9:1519. https://doi.org/10.3389/fonc.2019.01519.CrossRefPubMedPubMedCentral

Robinson BM. Malignant pleural mesothelioma: an epidemiological perspective. Ann Cardiothorac Surg. 2012;1(4):491–6. https://doi.org/10.3978/j.issn.2225-319X.2012.11.04.CrossRefPubMedPubMedCentral

Delgermaa V, Takahashi K, Park EK, Le GV, Hara T, Sorahan T. Global mesothelioma deaths reported to the World Health Organization between 1994 and 2008. Bull World Health Organ. 2011;89(10):716–24, 724A-724C. https://doi.org/10.2471/BLT.11.086678.CrossRefPubMedPubMedCentral

McDonald JC, McDonald AD. The epidemiology of mesothelioma in historical context. Eur Respir J. 1996;9(9):1932–42. https://doi.org/10.1183/09031936.96.09091932.CrossRefPubMed

Barbiero F, Giangreco M, Pisa FE, Negro C, Bovenzi M, Rosolen V, et al. Standardization of incidence rates of mesothelioma in the absence of national standards: sensitivity analysis in a cohort formerly exposed to asbestos. La Medicina del lavoro. 2016;4:307–14.

10.

Marinaccio A, Corfiati M, Binazzi A, Di Marzio D, Scarselli A, Ferrante P, et al. The epidemiology of malignant mesothelioma in women: gender differences and modalities of asbestos exposure. Occup Environ Med. 2018;75(4):254–62. https://doi.org/10.1136/oemed-2016-104119.CrossRefPubMed

11.

Consonni D, De Matteis S, Dallari B, Pesatori AC, Riboldi L, Mensi C. Impact of an asbestos cement factory on mesothelioma incidence in a community in Italy. Environ Res. 2020;183:108968. https://doi.org/10.1016/j.envres.2019.108968.CrossRefPubMed

12.

Oddone E, Bollon J, Nava CR, Minelli G, Imbriani M, Consonni D, et al. Forecast of malignant peritoneal mesothelioma mortality in Italy up to 2040. Int J Environ Res Public Health. 2020;18(1):160. https://doi.org/10.3390/ijerph18010160.CrossRefPubMedCentral

13.

Capecchi S, Iannario M. Gini heterogeneity index for detecting uncertainty in ordinal data surveys. METRON. 2016;74(2):223–32. https://doi.org/10.1007/s40300-016-0088-5.CrossRef

14.

Eliazar I, Sokolov IM. Maximization of statistical heterogeneity: from Shannon’s entropy to Gini’s index. Physica A. 2020;389(16):3023–38.CrossRef

15.

Abbott DM, Bortolotto C, Benvenuti S, Lancia A, Filippi AR, Stella GM. Malignant pleural mesothelioma: genetic and Microenviromental heterogeneity as an unexpected Reading frame and therapeutic challenge. Cancers (Basel). 2020;12(5):1186. https://doi.org/10.3390/cancers12051186.CrossRef

16.

Ngamwong Y, Tangamornsuksan W, Lohitnavy O, Chaiyakunapruk N, Scholfield CN, Reisfeld B, et al. Additive synergism between Asbestos and smoking in lung Cancer risk: a systematic review and meta-analysis. PLoS One. 2015;10(8):e0135798. https://doi.org/10.1371/journal.pone.0135798.CrossRefPubMedPubMedCentral

17.

Muscat JE, Wynder EL. Cigarette smoking, Asbestos exposure, and malignant mesothelioma. Cancer Res. 1991;51(9):2263–7.PubMed

18.

Segal A, Sterrett GF, Frost FA, Shilkin KB, Olsen NJ, Musk AW, et al. A diagnosis of malignant pleural mesothelioma can be made by effusion cytology: results of a 20 year audit. Pathology. 2013;45(1):44–8. https://doi.org/10.1097/PAT.0b013e32835bc848.CrossRefPubMed

19.

Negi Y, Kuribayashi K, Funaguchi N, Doi H, Mikami K, Minami T, et al. Early-stage Clinical Characterization of Malignant Pleural Mesothelioma. In Vivo. 2018;32(5):1169–74. https://doi.org/10.21873/invivo.11360.CrossRefPubMedPubMedCentral

20.

Kato K, Gemba K, Fujimoto N, Aoe K, Takeshima Y, Inai K, et al. Pleural irregularities and mediastinal pleural involvement in early stages of malignant pleural mesothelioma and benign asbestos pleural effusion. Eur J Radiol. 2016;85(9):1594–600. https://doi.org/10.1016/j.ejrad.2016.06.013.CrossRefPubMed

21.

Hjerpe A, Abd Own S, Dobra K. Integrative approach to cytologic and molecular diagnosis of malignant pleural mesothelioma. Transl Lung Cancer Res. 2020;9(3):934–43. https://doi.org/10.21037/tlcr-2019-pps-10.CrossRefPubMedPubMedCentral

22.

Cardinale L, Ardissone F. Diagnostic Imaging and Workup of Malignant Pleural Mesothelioma. Acta Biomed. 2017;88(2):134–42. https://doi.org/10.23750/abm.v88i2.5558.CrossRefPubMedPubMedCentral

23.

Wang ZJ, Reddy GP, Gotway MB, Higgins CB, Jablons DM, Ramaswamy M, et al. Malignant pleural mesothelioma: evaluation with CT, MR imaging, and PET. Radiographics. 2004;24(1):105–19. https://doi.org/10.1148/rg.241035058.CrossRefPubMed

24.

Tamer Dogan O, Salk I, Tas F, Epozturk K, Gumus C, Akkurt I, et al. Thoracic computed tomography findings in malignant mesothelioma. Iran J Radiol. 2012;9(4):209–11. https://doi.org/10.5812/iranjradiol.8764.CrossRefPubMedPubMedCentral

25.

Associazione Italiana di Oncologia Medica (AIOM), website at https://www.aiom.it/wpcontent/uploads/2019/10/2019_LG_AIOM_Mesotelioma.pdf

26.

Berzenji L, Van Schil PE, Carp L. The eighth TNM classification for malignant pleural mesothelioma. Transl Lung Cancer Res. 2018; 7(5):543–549. doi: https://doi.org/10.21037/tlcr.2018.07.05

27.

Gomez D, Tsao AS. Local and systemic therapies for malignant pleural mesothelioma. Curr Treat Options in Oncol. 2014;15(4):683–99. https://doi.org/10.1007/s11864-014-0314-4.CrossRef

28.

National Comprehensive Cancer Network (NCCN) website at, https://www.nccn.org/store/login/login.aspx? ReturnURL=https://www.nccn.org/professionals/physician_gls/pdf/mpm.pdf

29.

Buikhuisen WA, Hiddinga BI, Baas P, van Meerbeeck JP. Second line therapy in malignant pleural mesothelioma: a systematic review. Lung Cancer. 2015;89(3):223–31. https://doi.org/10.1016/j.lungcan.2015.06.018.CrossRefPubMed

30.

de Gooijer CJ, Baas P, Burgers JA. Current chemotherapy strategies in malignant pleural mesothelioma. Transl Lung Cancer Res. 2018;7(5):574–83. https://doi.org/10.21037/tlcr.2018.04.10.CrossRefPubMedPubMedCentral

31.

Mensi C, Riboldi L, De Matteis S, Bertazzi PA, Consonni D. Impact of an asbestos cement factory on mesothelioma incidence: global assessment of effects of occupational, familial, and environmental exposure. Environ Int. 2015;74:191–9. https://doi.org/10.1016/j.envint.2014.10.016.CrossRefPubMed

32.

Scherpereel A, Opitz I, Berghmans T, Psallidas I, Glatzer M, Rigau D, et al. ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma. Eur Resp J. 2020;55(6):1900953. https://doi.org/10.1183/13993003.00953-2019.CrossRef

Title: Integrating data from multidisciplinary Management of Malignant Pleural Mesothelioma: a cohort study
Authors: Laura Saracino
Chandra Bortolotto
Stefano Tomaselli
Elia Fraolini
Matteo Bosio
Giulia Accordino
Francesco Agustoni
David M. Abbott
Emma Pozzi
Dimitrios Eleftheriou
Patrizia Morbini
Pietro Rinaldi
Cristiano Primiceri
Andrea Lancia
Patrizia Comoli
Andrea R. Filippi
Giulia M. Stella
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Pleural Mesothelioma
Pleural Effusion
Pleural Mesothelioma
Mesothelioma
Published in: BMC Cancer / Issue 1/2021
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-021-08532-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2021

The importance of choosing the right strategy to treat small cell carcinoma of the cervix: a comparative analysis of treatments

Triplet versus doublet neoadjuvant chemotherapy regimens for locally advanced gastric cancer: a propensity score matching analysis

Acute limb ischemia in a cancer patient has high morbidity, high mortality, and atypical presentation: a tertiary cancer center’s retrospective study

Health-related quality of life in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation: results from the randomized phase III ALCYONE trial

Angiogenesis-related lncRNAs predict the prognosis signature of stomach adenocarcinoma

The combined effect of dichloroacetate and 3-bromopyruvate on glucose metabolism in colorectal cancer cell line, HT-29; the mitochondrial pathway apoptosis

Keynote webinar | Spotlight on antibody–drug conjugates in cancer